

**Supplemental Table S1.** Sequence of oligonucleotide primers used.

<b>Gene name</b>	<b>Forward Primer</b>	<b>Reverse Primer</b>
DSG1	AAA GCA CTG AAC CAG TTT GC	CAC AGA GGG CTT CAG AGT GT
DSP	TGT ACG ACT GGA GCG ACA AG	GCG TCT GCA GAG TGT CCA TA
TJP	CGT GCT GAC TTC TGG AGA TT	CTC TTG CCA GCT TTT CTC TG
E-Cadherin	CTGAGAACGAGGCTAACG	TTCACATCCAGCACATCC
TBP	GATAAGAGAGCCACGAACCAC	CAAGAACTTAGCTGGAAAACCC
IL-8	TAG CAA AAT TGA GGC CAA GG	AGC AGA CTA GGG TTG CCA GA
IL-1 $\beta$	TTC GAC ACA TGG GAT AAC GA	TCT TTC AAC ACG CAG GAC AG
CXCL1	AGG GAA TTC ACC CCA AGA AC	CAC CAG TGA GCT TCC TCC TC
CXCL2	CAC TCA AGA ATG GGC AGA AA	CCT CTG CAG CTG TGT CTC TC

**Supplemental Table 2.** List of antibodies used in the study, and their source

<b>Antibody</b>	<b>Source</b>	<b>Catalog Number</b>
Anti-Desmoglein1	Santa Cruz Biotechnology	SC-20114
Anti-Desmoplakin I/II	Santa Cruz Biotechnology	SC-33555
Anti-ZO-1	Santa Cruz Biotechnology	SC-10804
Anti-E-Cadherin	BD Biosciences	610182
Anti-NF- $\kappa$ B	Cell Signaling Technology	6956, 8242
Anti-I $\kappa$ B $\alpha$	Cell Signaling Technology	4814
Anti-TBP	Cell Signaling Technology	44059
Anti-Actin	Cell Signaling Technology	8457